Literature DB >> 16868969

Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis.

Rommel P Lu1, Gary Keilson.   

Abstract

Acute disseminated encephalomyelitis (ADEM) is a demyelinating disease of the central nervous system that is associated with significant morbidity and mortality. Early recognition of the disease is of paramount importance; however, treatment options are limited because only case reports and small series are available in the literature. We report a case of a 42 year-old previously healthy man, whom we treated successfully with a combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868969     DOI: 10.1002/jca.20103

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  5 in total

1.  Acute demyelinating disorders of the central nervous system.

Authors:  Meghan K Harris; Amir Hadi Maghzi; Masoud Etemadifar; Roger E Kelley; Eduardo Gonzalez-Toledo; Alireza Minagar
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 2.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

3.  Cyclosporine in the treatment of a case of fulminant and refractory acute disseminated encephalomyelitis.

Authors:  Mohammd-Mehdi Taghdiri; Ali Amanati; Babak Abdolkarimi
Journal:  Iran J Pediatr       Date:  2011-12       Impact factor: 0.364

4.  Treatment of acute disseminated encephalomyelitis.

Authors:  Daniela Pohl; Silvia Tenembaum
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

5.  Refractory Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an Adult.

Authors:  Federico Rodríguez-Porcel; Alejandro Hornik; Jordan Rosenblum; Ewa Borys; José Biller
Journal:  Front Neurol       Date:  2014-12-23       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.